Table 2. Switch constellations between first and second initiated biologic therapy for severe asthma in the GAN registry 2011 – 2024.
| Initial biologic | ||||||
|---|---|---|---|---|---|---|
| Second biologic | anti-IgE (n = 634) | anti-IL5R (n = 693) | anti-IL5 (n = 670) | anti-IL4R (n = 417) | anti-TSLP (n = 235) | Total |
| No switch documented | 540 (85.2%) | 588 (84.5%) | 533 (79.6%) | 379 (90.9%) | 231 (98.3%) | 2,271 (85.7% |
| Anti-IL5R | 15 (2.4%) | – | 64 (9.6%) | 14 (3.4%) | – | 93 (3.5%) |
| Anti-IL5 | 28 (4.4%) | 18 (2.6%) | – | 3 (0.7%) | – | 49 (1.8%) |
| Anti-IL4R | 28 (4.4%) | 59 (8.5%) | 53 (7.9%) | – | 3 (1.3%) | 143 (5.4%) |
| Anti-IgE | – | 2 (0.3%) | 4 (0.6%) | 3 (0.7%) | 1 (0.4%) | 10 (0.4%) |
| Anti-TSLP | 23 (3.6%) | 26 (3.8%) | 16 (2.4%) | 18 (4.3%) | – | 83 (3.1%) |
| Total who switched | 94 (14.8%) | 105 (15.2%) | 137 (20.4%) | 38 (9.1%) | 4 (1.7%) | 378 (14.3%) |
| Duration of initial biologic before switch (months) (median, IQR) | 19.87 (11.90 – 46.36) |
22.36 (12.16 – 33.54) |
24.23 (12.15 – 42.44) |
14.43 (7.84 – 32.36) |
10.90 (8.59 – 12.51) |
|
GAN = German Asthma Net; anti-IgE = anti-immunoglobulin E; anti-IL5 = anti-interleukin-5; anti-IL5R = anti-interleukin-5 receptor; anti-IL4R = anti-interleukin-4 alpha receptor; anti-TSLP = anti-thymic stromal lymphopoietin; IQR = interquartile range.